# A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct07116616/  
OnCo record `nct07116616` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of mRNA-2808 in multiple myeloma, run by ModernaTX, Inc., now recruiting.

## Summary

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT07116616 by ModernaTX, Inc., with 166 participants planned, started 2025-09-30 and due to reach its primary completion in 2030-06-17. Interventions recorded: mRNA-2808.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07116616
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Sponsor: ModernaTX, Inc.
- Enrolled: 166

## Sources

- ClinicalTrials.gov NCT07116616: https://clinicaltrials.gov/study/NCT07116616

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)

---
JSON: https://onco.cc/api/v1/entities/nct07116616.json